The new facility, located one hour from Frankfurt, will offer European device manufacturers a centrally-located site for ISO 10993-18 testing requirements and provide further conveniences for exhaustive extraction, FTIR, GC-MS, LC-MS and ICP-MS services in the region.
“NAMSA is excited to add to its global portfolio of services with the introduction of its new Obernburg laboratory,” commented Ulrich Gohlke, Director of German Lab Operations, NAMSA. “NAMSA is proud of its strong working relationships with EU regulatory entities, including the European Commission, and demonstrated track record of delivering significant time and cost savings throughout the medical device development continuum. With the introduction of NAMSA’s new Analytical Services Laboratory, we look forward to providing European device makers significant development efficiencies, including closer collaboration through an ideally-located testing partner.”
NAMSA is a Contract Research Organization (CRO)—and the world’s only Medical Device Organization (MRO)—that supports clients throughout all stages of the medical device development lifecycle. From concept and feasibility testing to post-market surveillance, services provided by NAMSA have been proven to accelerate time-to-market and reduce costs for product research and market introduction. By leveraging a half century of technical expertise, and drawing upon 1,000 highly knowledgeable global Associates, NAMSA is an industry leader in balancing speed and quality with proven scientific approaches.